ubmslateRN-logo-ubm

RN Mobile Menu

Search form

Topics:

Biosimilars

Biosimilars

EULAR 2017 (Photo courtesy of EULAR_6282)

EULAR 2017 wraps on Saturday. In this slideshow, we highlight some of the most popular presentations from the meeting.

©Zonda/Shutterstock.com

The biosimilar adalimumab-atto is equivalent to its reference product — which it slightly outperformed in this trial.

(Injection of a vaccine  ©thodonal88/Shutterstock.com)

Vaccine efficacy in RA, biosimilar safety and the danger of steroid injections for knee osteoarthritis top this week's research roundup. In this slideshow, we feature these and other recent research findings from the key journals.

(©KPG_Payless/Shutterstock.com)

Clinical trial shows that switching from the infliximab originator to its biosimilar does not compromise safety or effectiveness of treatment.

@Planar/Shutterstock.com

Etanercept-szzs (Erelzi, Sandoz) has been approved by the U.S. Food and Drug Administration for RA and more.

©lenetstan/Shutterstock.com

A new report confirms that discounts for biosimilars do not determine global uptake and prescription incentives to encourage the use of biosimilars are hit and miss.

©Zonda/Shutterstock.com

Biosimilars to Humira and Enbrel are one step closer to the marketplace with FDA advisory committee approval.

Pages

Subscribe to Biosimilars on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.